
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune is a clinical-stage biotechnology company with a broad pipeline of therapeutic and diagnostic products targeting neurodegenerative diseases, including Alzheimer's and Parkinson's. Their expertise in precision medicine and use of proprietary technology platforms sets them apart from competitors. With a strong pipeline and potential for partnering agreements, AC Immune has significant potential for long-term growth.
Bears say
AC Immune is an established drug development company, and as with any company in this industry, it faces many risks such as unexpected outcomes in clinical trials, regulatory uncertainty, and complex and price-sensitive commercial markets. Additionally, the company had a net loss of CHF 14.8M for the quarter and expects current cash resources to cover operations for the next 12 months. This, combined with decreased R&D expenses, may indicate a lack of progress or potential setbacks in their pipeline.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares